Late-Phase Semi-Solid & Liquid Drug Product Development
Advancing Late-Phase Development to Commercial-Ready Reality
In late-phase development, CPL focuses on tightening processes, data, and controls so your semi-solid and non-sterile liquid products are truly launch-ready. We refine formulations, finalize CPPs (Critical Process Parameters) and CQAs (Critical Quality Attributes), and execute registration and scale-up batches under cGMP. Integrated analytical method validation, stability programs, and in vitro performance testing support robust CMC packages for NDA, ANDA, and 505(b)(2) filings, helping you move confidently from Phase II/III through approval and into reliable commercial supply.
Integrated Late-Phase Development for Semi-Solids & Liquids
As products advance into Phase II/III, CPL unites formulation, process, analytical, and product testing expertise to lock in robustness, support registration and PPQ batches, and prepare for commercial launch.
Late-Phase Product & Formulation Optimization
From fine-tuning formulations to confirming long-term stability and in-use performance, CPL optimizes semi-solid and non-sterile liquid formulations for late-phase success. We refine lead formulations based on clinical and stability data, confirm manufacturability at target scales, and mitigate unresolved risks. By aligning formulation decisions with CPPs, CQAs, and commercial equipment constraints, we help sponsors finalize robust, registration-ready formulations.
Discover Product & Formulation Development Capabilities
Process Characterization
In late-phase development, manufacturability means proven, reproducible performance. CPL’s teams characterize processes for semi-solids and non-sterile liquids, map CPPs to CQAs, execute engineering and PPQ batches, and tighten controls for commercial readiness. We address any process and contamination control challenges, then translate processes to commercial lines. Documentation, master batch records, and risk assessments are aligned with cGMP and regulatory expectations to support smooth inspections and approvals.
Learn More
Analytical Method Validation for Registration & Commercial Use
As development advances, analytical methods must be fully validated and capable of supporting PPQ, stability, and ongoing commercial release. CPL finalizes and validates methods for creams, ointments, gels, lotions, solutions, suspensions, and sprays, addressing complex needs such as content uniformity, particle size control, and impurity profiling. Using ICH Q2-aligned validation, we confirm accuracy, precision, robustness, and specificity under real-world cGMP conditions. The result is a reliable analytical toolkit that underpins NDA, ANDA, and 505(b)(2) submissions and routine commercial control.
Explore Analytical Method Development
Late-Phase Product Testing & Registration Support
CPL’s QC and analytical laboratories provide the comprehensive release, stability, and performance testing demanded in late-phase development and registration. We design and execute ICH-aligned stability programs, comparability studies, and IVRT to support shelf-life, post-approval change strategies, and bioequivalence for generic products. All data are generated under cGMP and structured to fit seamlessly into CMC sections of NDA, ANDA, and 505(b)(2) filings, helping sponsors move confidently toward approval and launch.
View Product Testing Capabilities
Registration & Commercial-Scale Manufacturing
CPL’s clinical, registration, and commercial manufacturing services provide a reliable bridge from late-phase development to sustained market supply for semi-solid and non-sterile liquid drug products. With batch sizes from 20kg to 5,000kg, we support registration batches, PPQ, validation batches, commercial launch, and ongoing commercial supply under rigorous cGMP. Our experience with topical, nasal, and oral liquid formulations, combined with integrated packaging and serialization, ensures each batch meets regulatory expectations and market demand, from pivotal trials through long-term lifecycle management.
Learn More About Our Manufacturing Capabilities
Packaging & Labeling
CPL’s primary and secondary packaging is tightly integrated with late-phase clinical and commercial manufacturing, enabling precision filling and launch-ready presentation. Automated and semi-automated lines handle tubes, bottles, and foil sachets, with options such as nitrogen blanketing, intrinsically safe (XP) lines, and specialized closures, including droppers, pumps, airless and child-resistant caps, and overcaps. Primary packaging flows seamlessly into secondary operations, including cartoning, inserts, labeling, and tamper-evident features, all under cGMP control and on-site QC, supporting an efficient, inspection-ready supply for global clinical trials.
Discover Packaging & Labeling CapabilitiesCPL Experience Spotlight
Clinical Batch Process Adjustment Needed for Topical Gel
Dedicated to Excellence
from Molecule to Commercialization
CPL supports programs from early-phase through commercial launch, combining preformulation insight, robust semi-solid and non-sterile liquid development, scalable process design, and clinical and commercial manufacturing.
Pharmaceutical Development Services
Pharmaceutical Development Services
Comprehensive expertise that turns molecules into scalable, compliant, market‑ready semi-solid and non-sterile therapies.
Analytical & Product Testing
Analytical & Product Testing
Robust analytics power confident development and manufacture of topical and non-sterile liquid products.
Clinical & Commercial Manufacturing
Clinical & Commercial Manufacturing
More than three decades of GMP manufacturing experience from clinical supply through commercialization.
Packaging, Labeling & Serialization
Packaging, Labeling & Serialization
Integrated packaging, serialization, and aggregation ensure compliant, continuous commercial supply.
Semi-Solid & Non-Sterile Liquid Expertise
Semi-Solid & Non-Sterile Liquid Expertise
Pure-play CDMO for semi-solids and non-sterile liquids, with advanced micro encapsulation capabilities.
Unique Product Handling Experience
Unique Product Handling Experience
Infrastructure and expertise to manage complex, higher-risk semi-solid and non-sterile liquid products.
FAQs
-
CPL is a specialist pharma CDMO focused on semi-solids and non-sterile liquids, supporting late-phase optimization for creams, ointments, gels, lotions, solutions, and suspensions. Services include formulation refinement, process characterization, registration batch manufacturing, analytical method validation, and late-phase product testing. Our integrated approach prepares drug products for NDA, ANDA, and 505(b)(2) submissions and smooth transition into commercial GMP manufacturing in the pharmaceutical industry.
-
Our late-phase teams conduct structured process characterization and pharmaceutical process validation for topical and non-sterile liquid formulations. We map CPPs to CQAs, perform risk and gap assessments, and run engineering, registration, and PPQ batches. By understanding mixing, homogenization, thermal profiles, and hold times at scale, we de-risk tech transfer, simplify inspections, and support robust, reproducible processes ready for commercial manufacturing.
-
CPL’s analytical development and product testing services are built around late-phase regulatory needs. We perform analytical method validation (ICH Q2) and ICH-compliant stability studies. Performance testing, IVPT/IVRT (where applicable), and comprehensive QC data support registration batch manufacturing, CMC sections of NDA/ANDA/505(b)(2) filings, comparability exercises, and post-approval change control.
-
In addition to very early phase development, CPL offers GMP late-phase clinical trial manufacturing services and commercial-ready batch production for semi-solids and non-sterile liquids, including topical products, nasal sprays, oral suspensions, and other non-sterile liquid pharmaceuticals. We combine registration and PPQ batches, integrated supply chain management, and container closure system expertise with rigorous quality control testing. The result is reliable late-phase clinical supply and a clear, de-risked path to commercial launch and ongoing market supply.
Commitment.
Partnership. Legacy.
Leverage CPL’s 35 years of expertise in non-sterile liquids and semi-solids to ensure your program's success. We’ll support your product from molecule to market, or step in at any stage of its product lifecycle.
